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AbsTrACT
Introduction ’One-off’ systematic case-finding for 
cOPD using a respiratory screening questionnaire is 
more effective and cost-effective than routine care at 
identifying new cases. However, it is not known whether 
early diagnosis and treatment is beneficial in the longer 
term. We estimated the long-term cost-effectiveness of a 
regular case-finding programme in primary care.
Methods a Markov decision analytic model was 
developed to compare the cost-effectiveness of a 
3-yearly systematic case-finding programme targeted to 
ever smokers aged ≥50 years with the current routine 
diagnostic process in UK primary care. Patient-level data 
on case-finding pathways was obtained from a large 
randomised controlled trial. information on the natural 
history of cOPD and treatment effects was obtained 
from a linked cOPD cohort, UK primary care database 
and published literature. the discounted lifetime cost per 
quality-adjusted life-year (QalY) gained was calculated 
from a health service perspective.
results the incremental cost-effectiveness ratio of 
systematic case-finding versus current care was £16 596 
per additional QalY gained, with a 78% probability of 
cost-effectiveness at a £20 000 per QalY willingness-
to-pay threshold. the base case result was robust to 
multiple one-way sensitivity analyses. the main drivers 
were response rate to the initial screening questionnaire 
and attendance rate for the confirmatory spirometry test.
Discussion regular systematic case-finding for 
cOPD using a screening questionnaire in primary care 
is likely to be cost-effective in the long-term despite 
uncertainties in treatment effectiveness. Further 
knowledge of the natural history of case-found patients 
and the effectiveness of their management will improve 
confidence to implement such an approach.
InTroDuCTIon
COPD is one of the most common long-term condi-
tions with significant public health impact, costing 
over £1.5 billion per annum to the UK National 
Health Service (NHS),1 largely due to emergency 
hospital admissions among patients experiencing 
exacerbations and costs of maintenance medica-
tion.2 Despite considerable health service use,3 
it is thought that perhaps half of all subjects with 
this disease still remain undiagnosed.4 Smoking 
cessation interventions, pharmacotherapy and 
non-pharmacological approaches such as pulmo-
nary rehabilitation and self-management can reduce 
morbidity, particularly the frequency of exacerba-
tions and prolong the life of patients diagnosed 
of COPD.5–9 Observed benefits might be even 
greater if undiagnosed patients were found earlier 
and appropriate treatment commenced, although 
evidence to support this is currently limited.10
A number of small uncontrolled studies of 
different approaches to identify patients with undi-
agnosed COPD from primary care and other settings 
have been undertaken,11 but there are few appro-
priately designed trials to address this issue. We 
recently conducted the largest cluster randomised 
controlled trial (TargetCOPD)12 to evaluate two 
alternative systematic approaches to identify undi-
agnosed symptomatic patients compared with 
routine practice (no systematic case-finding). The 
systematic strategies consisted of opportunistic 
case-finding, where a respiratory screening ques-
tionnaire was administered when eligible patients 
attended their primary care practice for consulta-
tion, and an active approach, where patients were 
Key messages
What is the key question?
 ► What is the long-term cost-effectiveness of 
undertaking a regular programme of case-
finding and early detection of COPD?
What is the bottom line?
 ► Health economic decision modelling found that 
systematic case-finding among ever-smokers 
aged 50 years and over on a 3-yearly basis is 
highly likely to be cost-effective compared with 
routine practice.
Why read on?
 ► Currently, case-finding programmes for COPD 
are not being implemented internationally 
due to the lack of evidence on the long-
term benefits and cost-effectiveness of early 
diagnosis, and this paper presents the first 
analysis of the long-term cost-effectiveness of 
systematic case-finding for undiagnosed COPD.
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additionally invited by mail to complete the same questionnaire. 
In both cases, symptomatic patients were then invited for diag-
nostic spirometry. Over the 1-year trial period, active case-
finding was the most effective and cost-effective approach to 
identify new cases (OR=7.5 (95% CI 4.80 to 11.55); £333 per 
additional case detected) compared with routine practice.
Although short-term clinical and cost-effectiveness of a single 
‘one-off ’ programme of case-finding was demonstrated, this 
does not necessarily translate into future long-term benefits for 
a regular programme. Furthermore, the results of the economic 
analysis (cost per case detected) are not easily comparable with 
results from other health programmes.13 In the absence of long-
term trial data, model-based economic evaluations are needed.14 
We report the results of a model-based economic evaluation of the 
long-term costs and benefits of a regular programme of system-
atic active case-finding over routine practice, using data from 
the TargetCOPD trial,12 the linked Birmingham COPD cohort,15 
a large primary care database and the published literature. The 
model outcome is expressed in cost per quality-adjusted life-year 
(QALY) gained, a measure where a cost-effectiveness decision 
threshold rule exists in the UK.16
MeThoDs
study design and intervention
A Markov decision model was built with TreeAgePro 2015 
(TreeAge Software, Williamstown, Massachusetts, USA) to esti-
mate the long-term cost-effectiveness of systematic active case-
finding for COPD among ever-smokers without a prior diagnosis 
of COPD in primary care versus routine practice. A cost–utility 
analysis was undertaken to calculate the cost per QALY gained 
from a health service perspective (the UK NHS).
The model was based on the methods in our published case-
finding trial, using data from the most effective strategy iden-
tified in the trial (‘active’ case-finding) compared with routine 
care.12 17 The population in the trial comprised ever smokers 
aged 40–79 years without a prior diagnosis of COPD. However, 
for this long-term model, we chose a starting cohort of those 
aged 50 years, as few patients were identified below this age in 
the trial.12
For the active case-finding approach, eligible patients were 
identified through electronic health records using a standardised 
search and their records ‘flagged’. Flagged patients were offered 
a respiratory symptom screening questionnaire at any routine 
practice visit and were also sent the questionnaire by mail with 
a reply-paid envelope with up to two reminders. Patients who 
reported relevant chronic respiratory symptoms on the question-
naire were invited for a confirmatory spirometry test to diagnose 
COPD according to UK criteria.18 Routine practice was defined 
according to UK and international guidance,19 which recom-
mends spirometric confirmation of COPD among those over 
the age of 35 years who have a risk factor (generally smoking) 
and who present with exertional breathlessness, chronic cough, 
regular sputum production, frequent winter ‘bronchitis’ or 
wheeze.18 Case-finding was a one-off activity in the TargetCOPD 
trial, but in this study, we have assumed that the intervention 
would be repeated every 3 years.
Model structure
Patients without a prior COPD diagnosis in each strategy moved 
between 14 mutually exclusive health states over their lifetime 
(figure 1). The health states were grouped into three broad 
disease categories: disease free, undiagnosed disease, diagnosed 
disease and dead. Patients with no airflow obstruction, either 
with or without respiratory symptoms, were classified as ‘disease 
free’. Those with relevant respiratory symptoms and airflow 
obstruction were classified as either remaining undiagnosed or 
becoming diagnosed. A diagnosis required either a new health 
record of a COPD diagnosis through routine care or receiving 
a diagnosis through the case-finding programme.18 20 COPD 
health states were defined according to the traditional Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) severity 
classification with stages 1–4 based on airflow obstruction21 
in line with previous Markov models on the management of 
COPD.22 However, the GOLD stage 4 health state was not made 
available for undiagnosed patients as virtually no patients were 
newly identified as severe as GOLD stage 4 in previous case-
finding studies.11 12 The model had a time cycle of 3 months; 
short enough to capture important COPD-related events such 
as exacerbations.23 The time horizon was 50 years assuming a 
maximum age of 100 years.
The base case starting cohort of patients was distributed across 
five of the thirteen health states, in line with the patient distri-
bution observed in the TargetCOPD trial for the 50-year-old 
age group, where 52.7% were male (table 1).12 A percentage 
of 43.0% had no respiratory symptoms, 48.2% had symptoms 
but no airflow obstruction, and the remaining 8.8% were new 
COPD cases that were undiagnosed prior to participating in the 
trial. Among these newly diagnosed patients, 69.0%, 27.4% and 
3.6% had COPD GOLD stages 1, 2 and 3, respectively.
Transitions at every 3-month cycle were based on several 
assumptions to approximate the natural history and current 
management of COPD. Only patients who had developed symp-
toms could progress to any of the categories of undiagnosed 
COPD. Once a patient developed COPD, the model allowed 
movement to the immediate next worse GOLD stage. Direct 
deterioration beyond the next stage within a 3-month period 
was not allowed because COPD was assumed to progress slowly 
(e.g. movements from GOLD 1 directly to 3 and from GOLD 
2 to 4 were not allowed). Transition from an undiagnosed to a 
diagnosed health state was permitted but not the reverse. Not all 
diagnosed patients received treatment (figure 2). Improvements 
were only permitted in treated patients. Undiagnosed GOLD 
stage health states were assumed to have the same baseline tran-
sitions to worse undiagnosed GOLD stages as diagnosed health 
states. Finally, there was a risk of exacerbation and death in a 
3-month time cycle within any health state. The case-finding 
processes were modelled as events within each health state 
(figure 1). Systematic case-finding only occurred every 3 years, 
although a new diagnosis of COPD could arise through routine 
care in either strategy in every cycle.
Data values used in the model
Most of the data related to the process of case-finding and diag-
nosis of COPD were derived from the active arm of the Target-
COPD trial12 and the associated Birmingham COPD cohort 
study15 (table 1 and table 2). Transition probabilities between 
GOLD stages were obtained from The Health Improvement 
Network (THIN) database, which holds longitudinal primary 
care information on over 11 million UK patients, including 
about 2 million with diagnosed COPD24 (see supplementary 
material for detailed estimation methods).
For pragmatic reasons, only severe exacerbations (i.e., those 
requiring inpatient stay25 were considered in this evaluation as 
these episodes alone account for over 84% of all COPD-related 
healthcare costs.26 The annual rate of severe exacerbations by 
undiagnosed and diagnosed GOLD stage was obtained from 
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Figure 1 Transitions between model health states.
baseline data from the Birmingham COPD cohort.15 The rates 
were converted to quarterly transition probabilities and beta 
distributions were fitted about the point estimates.
Age-specific and sex-specific all-cause mortality rates were 
obtained from the life tables for England and Wales27 and 
applied to patients without COPD (online supplementary table 
S1). Rates were adjusted to avoid double counting COPD-related 
mortality. Age-specific all-cause mortality rates for diagnosed 
COPD patients were derived from the annual transition matrix 
generated from the THIN database (online supplementary table 
S7). COPD-adjusted all-cause mortality for the ‘disease free’ 
cohort was derived from the UK life tables (online supplemen-
tary table S1).
Prescription patterns in UK primary care show 29.6% of 
patients with COPD receive a long-acting beta-agonist (LABA)-
based inhaled medication (excluding long-acting muscarinic 
antagonists (LAMA)), 9.5% receive a LAMA-based combination 
(excluding LABA), and 25.0% receive combinations that include 
LABA+LAMA.28 Treatment effects from published systematic 
reviews suggest reductions in risk of exacerbations of up to 27% 
(OR=0.73) for some dual inhaler combinations with further 
reductions for triple drug combinations.9 It was not practical 
to model treatment effects for each COPD inhaler combina-
tion on each type of outcome; therefore, a conservative simpli-
fying assumption was made, using the point estimates from a 
meta-analysis of the effect of a single LAMA versus placebo on 
mortality (OR=0.98) and severe exacerbation (OR=0.85).29 
The published evidence was largely based on patients with a 
FEV1 <60%, but the effect was assumed to be similar across all 
GOLD stages, although emerging evidence shows that patients 
with FEV1 >60% may have even greater capacity to benefit from 
early treatment.30
Only 29.3% of newly diagnosed patients were modelled to 
commence treatment annually.28 This annual rate was derived 
from a study that showed 82.7% of patients with COPD in the 
UK were on treatment 5 years post-diagnosis. This is likely to be 
a conservative estimate as reports from other countries suggest 
treatment initiation rates to be higher.31
Utility values for undiagnosed and diagnosed GOLD stages 
1–4 health states were derived from baseline data from the 
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Table 1 General model parameters related to case-finding processes
Parameter Value α β
Starting cohort characteristics (percentage)*12
  Male 52.7 5999 5394
  Asymptomatic without COPD 43.0 364 482
  Symptomatic without COPD 48.2 364 482
  Undiagnosed COPD 8.8 74 772
  Proportion in GOLD stage 1 69.0 58 26
  Proportion in GOLD stage 2 27.4 23 61
  Proportion in GOLD stage 3 3.6 3 81
Natural history of development of COPD (percentage 
per year)
  Development of symptoms†46 47 2.0 135 6775
  Incidence of COPD*‡ 48 .6 55 9945
  Proportion of incident cases in GOLD stage 1§49 72.2 44 17
  Proportion of incident cases in GOLD stage 2§49 27.8 17 44
Routine practice (percentage)12
  Probability of being diagnosed with COPD 0.8 337 41 692
  Treatment after COPD diagnosis 29.3 3972 9585
Systematic case-finding activities (percentage)12
  Received questionnaire 99.9 12 175 1
  Responded to questionnaire 35.5 846 1572
  Reported symptom on questionnaire among 
responders
56.4 482 364
  Spirometry conducted in those reporting symptoms 66.1 559 287
  Diagnosed with COPD in those attending 
spirometry
39.8 87 2331
Utility
  Asymptomatic without COPD15 0.8394 1522 291
  Symptomatic without COPD15 0.7549 8817 2862
Costs (£)12 Value α λ
  Postal questionnaire 4.01 99 39
  Booking and conducting spirometry test 55.27 24 0.5
Beta distribution: the symbols α and β are parameters that define a beta 
distribution, which is a continuous probability distribution bounded at the extremes 
by 0 and 1. The number of successes is α, while failure is β.
Gamma distribution: the symbols α and λ are parameters that define a gamma 
distribution, which is a continuous discrete distribution bounded at the extremes by 
0 and ∞. The mean of the distribution is α(1/λ) and variance is α(1/λ).2
*Age -dependent parameters. Values presented are for individuals aged 50- year-
olds.
†Based on clinical opinion, it was considered that incident cases account for 10% 
of prevalent cases (20%) of respiratory symptoms in the UK population, which was 
validated using values from Eagan (2002).
‡A longitudinal observational primary care database (Dutch Integrated Primary 
Care Information) follow-up study. The incidence rate was reported in 1000 person-
years, which was then converted to a 1-year probability.
§Cohort study of Danish general population at years 0, 5 and 15 (Copenhagen City 
Heart Study). Of symptomatic normal at baseline that later developed COPD 15 
years later, 72% and 28% had GOLD stages 1 and 2, respectively. This was assumed 
to be a fixed distribution.
Birmingham cohort,15 containing patients representative of a UK 
primary care COPD population in a stable condition and also 
symptomatic individuals without COPD. For individuals without 
symptoms, utility values were derived from a published age-ad-
justed algorithm, developed from utility values from the general 
population,32 as there was no utility value for ever-smokers in 
the general population in the literature. The model assumed that 
utility loss following severe exacerbation persisted for 3 months, 
in line with a previously published model.33 Disutility was 
modelled to be higher in the first month (50%) compared with 
the second (25%) and third (25%) month, after which quality 
of life was assumed to return to pre-exacerbation levels. This 
loss was applied to mean utility scores across all the four COPD 
severity levels.34 35
resource use and costs
The cost of systematic case-finding was estimated from the active 
arm of the TargetCOPD trial12 (tables 1 and 2, online supplemen-
tary table S3, table S4, table S5). Estimation of healthcare costs 
for the diagnosed and treated GOLD stages (table 2) followed 
existing costing frameworks.33 35 Cost of COPD-related inhaled 
pharmacotherapy was calculated using data from diagnosed 
patients in the Birmingham cohort. No cost was attached to 
routine care or comorbidities since these were assumed to be the 
same for both arms.
Unit costs were primarily from the Personal Social Services 
Research Unit,36 NHS reference costs and the British National 
Formulary.37 Costs were inflated to 2015 prices using the 
Hospital and Community Health Services inflation index36 
where necessary.
Assessment of cost-effectiveness
An incremental cost-effectiveness ratio (ICER) was calculated as 
a ratio of the mean difference in cost and the mean difference in 
QALY gained between systematic case-finding and routine practice 
and presented as cost per QALY gained. Discounting was applied to 
costs and outcomes at a rate of 3.5% in line with NICE guidance.16 
Where available, data were entered into the model as distributions 
in order to fully incorporate the uncertainty around parameter 
values, so that a probabilistic sensitivity analysis could be under-
taken. A gamma distribution was fitted for all cost parameters. A 
log-normal distribution, which accommodates the ratio nature of 
risk measures, was constructed for ORs. Beta distributions were 
fitted for all transition probabilities and utility estimates. The prob-
abilistic sensitivity analysis was run with 10 000 simulations, and 
cost-effectiveness planes and cost-effectiveness acceptability curves 
(CEAC) were produced. The CEAC is the standard method for 
quantifying the likelihood that an intervention is more cost-effective 
compared with an alternative.
Additional one-way sensitivity analyses
A series of one-way sensitivity analyses was conducted to assess 
how key parameters such as starting age of cohort, screening 
interval and time horizon affected the results. The impact of 
other important parameters such as questionnaire response 
rate, spirometry attendance rate, treatment initiation rates and 
the effectiveness of treatment with regards to exacerbations, 
mortality and quality of life gain were also explored.
resulTs
The base case results for 50-year-old ever-smokers (table 3) showed 
that compared with routine practice, a 3-yearly systematic active 
case-finding strategy was more expensive but more effective, with a 
greater number of QALYs gained over a lifetime time horizon. The 
difference in cost was £466, with 0.0281 QALYs gained, producing 
an ICER of £16 596 per QALY gained.
Results from the probabilistic sensitivity analysis 
(figure 3) showed all 10 000 resampled points were clus-
tered in the North-East quadrant, representing instances 
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Figure 2 Example of pathway for an undiagnosed patient with GOLD stage 3 during a 3-month systematic case-finding cycle.
Table 2 Model parameters related to disease progression and outcomes (per annum)
GolD 1 GolD 2 GolD 3 GolD 4 Dead
Transitions (probability)*24
  GOLD 1 0.9047 0.0876 0.0000 0.0000 0.0077
  GOLD 2 0.0510 0.9001 0.0362 0.0000 0.0128
  GOLD 3 0.0000 0.1044 0.8368 0.0324 0.0265
  GOLD 4 0.0000 0.0000 0.0936 0.8187 0.0877
Transition for symptomatic patients*
  Symptoms, no COPD48 49 0.0040 0.0015 0.0000 0.0000 0.0026†
Exacerbation (probability)
  Severe exacerbation‡15 0.0270 0.0760 0.2720 0.3480 –
  Mortality after severe exacerbation33 0.0703 0.0703 0.0703 0.0703 –
Treatment effect (OR)
  All-cause mortality29 0.9800 0.9800 0.9800 0.9800 –
  Severe exacerbation29 0.8500 0.8500 0.8500 0.8500 –
  Progression to the next GOLD stage§ 0.8500 0.8500 0.8500 0.8500 –
Costs (£)¶
  Scheduled GP and hospital visits19 164.56 267.06 394.01 541.06 –
  Inhaled medication33 485.16 567.84 735.96 824.52 –
  Inpatient stay due to exacerbation33 2263.00 2263.00 2263.00 2263.00 –
Health outcomes
  Utility‡15 0.7197 0.7013 0.6798 0.5855 –
  Disutility from severe exacerbation‡15 −0.2398 −0.2337 −0.2265 −0.1951 –
  Utility gained from treatment50 0.0367 0.0367 0.0367 0.0367 –
*Age -dependent parameters. Values presented are for individuals aged 50- years-old.
†Value represents mortality risk in the general population.
‡Birmingham COPD cohort: data from the Birmingham Lung Improvement StudieS: an ongoing series of studies aimed at evaluating better strategies for identifying and managing COPD in 
primary care.15 Disutility data shows utility loss over 1 year: 50% utility loss in the first month and 25% utility loss for the second and third month per cycle. The impact of exacerbations on quality 
of life is greater in patients with less severe disease who also tend to be younger.51
§Expert panel comprised consultant pulmonologists, epidemiologists and senior health economist. The panel was presented with results of prior scoping reviews on the effect of treatment on 
exacerbation, mortality and lung function, but there was no review transition between GOLD stages. Given that the OR in reviews were around 0.85, the panel agreed then that the odds of 
treatment slowing disease progression to the next worse GOLD stage should be 0.85 for the base case.
¶Cost method was adapted and unit costs were updated to 2015 price year.
where systematic case-finding was more expensive and 
more effective than routine practice. A percentage of 
78.4% of these points were below the £20 000/QALY will-
ingness-to-pay threshold (WTP),16 which represents the 
probability of systematic case-finding being cost-effective at 
that threshold. The CEAC shows the probability of cost-ef-
fectiveness at different WTP thresholds (online supplemen-
tary figure S1)
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Table 3 Base case result cost–utility analysis
Case-finding strategy 
Mean values Mean difference ICer
Cost (£) QAlYs Cost (£) QAlY (£/QAlY)
Routine care 1007.64 14.1767
Systematic case-finding 1473.51 14.2048 465.87 0.0281 16 596.28
ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life-years.
Figure 3 Cost-effectiveness plane for the comparison of systematic case-finding with routine care, based on 10 000 cost-effect pairs. QALY, quality-
adjusted life-year.
sensitivity analysis
Varying the age for starting screening altered both the interven-
tion costs and the QALYs gained (table 4). The most cost-effec-
tive age to begin screening in UK ever-smokers was estimated 
to be 60 years. Although the intervention costs were higher, the 
QALY gains from management of symptoms were also greater. 
Compared with younger age groups, a higher proportion of indi-
viduals aged 60 years had developed COPD during the first case-
finding cycle, and therefore did not incur the costs associated 
with case-finding in subsequent cycles. The individuals aged 60 
years were also young enough to maximally benefit from treat-
ment of their symptoms relative to older cohorts.
Annual case-finding yielded the most benefit but was the most 
expensive strategy, while a screening interval of 10 years had 
the lowest ICER thereby making the preferred screening interval 
from a cost-effectiveness perspective. The sensitivity analysis 
results also showed that the minimum required screening ques-
tionnaire response rate was 12% for systematic case-finding to 
remain cost-effective at the £20 000 per QALY threshold. Simi-
larly, systematic case-finding was only preferred to routine prac-
tice if more than 26% of those who were invited for spirometric 
confirmation attended the session.
The model was also sensitive to the effectiveness of treatment 
on disease outcomes. The opportunity cost of systematic case-
finding steadily increased as the effect of treatment worsened 
(figure 4). First, each variable was considered separately. When 
no impact on mortality was assumed, case-finding was still 
cost-effective at £17 663/QALY. No impact on exacerbations 
gave an ICER of £18 258/QALY. However, if no impact on 
progression (to worse GOLD stage) was assumed, the ICER rose 
to £22 943/QALY, and the threshold OR for cost-effectiveness 
at £20 000/QALY was 0.94. When the ORs for the effectiveness 
of treatment on all outcomes were simultaneously adjusted to 
1, systematic case-finding was not preferred over routine prac-
tice (online supplementary figure S2), with an ICER of £28 811/
QALY.
The model was also sensitive to the magnitude of the addi-
tional impact on quality of life, which was independent of the 
impact on quality of life and survival from progression, mortality 
and exacerbation (table 4). If the utility gain reduced to less than 
0.0269, then systematic case-finding was no longer cost-effective 
at £20 000/QALY. Assuming treatment had no additional impact 
on quality of life resulted in an ICER of £40 457/QALY. Another 
important determinant of cost-effectiveness was the treatment 
initiation rate. A systematic case-finding programme was cost-ef-
fective as long as treatment was initiated in at least 8% of previ-
ously untreated patients yearly (figure 4).
DIsCussIon
There are as yet no published primary studies that provide data 
on the long-term cost-effectiveness of a systematic programme 
of case-finding for undiagnosed COPD. In their absence, this 
novel economic model aims to address this unanswered ques-
tion using data from the best published sources available. We 
have shown that the systematic screening of ever-smokers aged 
50 years and over, every 3 years is potentially a cost-effective 
strategy according to UK cost-effectiveness thresholds. The 
results were supported by the majority of the sensitivity anal-
yses except in the most extreme scenarios. For case-finding 
to be cost-effective, a sufficient proportion of patients must 
respond to the initial screening questionnaire (12%) and attend 
the confirmatory spirometry test (26%). In our published trial, 
15% responded after the initial invite without a reminder12 and 
more than 63% of those invited attended the spirometry test. 
Crucially, 1 in 12 (8%) of previously untreated patients must 
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Table 4 Sensitivity analysis results
Cost difference QAlY difference
ICer
(£/QAlY)
Cohort age (years)
  40 356.32 0.0184 19 373.50
  50 465.87 0.0281 16 596.28
  60 520.27 0.0333 15 645.62
  70 448.61 0.0265 16 915.53
Screening interval (years)
  1 910.08 0.0465 19 586.35
  3 465.87 0.0281 16 596.28
  5 334.09 0.0210 15 922.52
  10 217.00 0.0143 15 219.88
Time horizon (years)
  20 316.94 0.0147 21 522.47
  30 411.87 0.0226 18 206.16
  40 458.44 0.0272 16 883.96
  50 465.87 0.0281 16 596.28
Spirometry attendance rate
  10.5% (threshold 2) 159.21 0.0054 29 556.13
  26.3% (threshold 1) 260.33 0.0130 20 097.49
  66.1% (base case) 465.87 0.0281 16 596.28
Questionnaire response rate
  4.0% (threshold 2) 122.88 0.0040 30 364.90
  11.6% (threshold 1) 219.19 0.0109 20 056.90
  35.0% (base case) 465.98 0.0281 16 595.80
Utility gain from treatment
  0.0000 465.87 0.0115 40 456.80
  0.0092 (threshold 2) 465.87 0.0155 30 011.41
  0.0269 (threshold 1) 465.87 0.0233 19 999.67
  0.0367 (base case) 465.87 0.0281 16 596.28
Threshold 1=willingness-to-pay threshold at £20 000 per QALY.
Threshold 2=willingness-to-pay threshold at £30 000 per QALY.
Questionnaire response rate after the initial invite in the TargetCOPD trial=15% 
(2312/15 387).12
Questionnaire response rate after the first reminder in the TargetCOPD trial=25% 
(3936/15 387).12
Base case values are in bold fonts.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
also be started on treatment yearly for systematic case-finding 
to remain cost-effective. Data from long-term follow-up for 
the TargetCOPD trial suggests that 12 months after diagnosis, 
21% of case-found patients in the active case-finding arm were 
on the practice COPD Quality Outcomes Framework (QOF) 
register, suggesting they were likely to be receiving some treat-
ment. Mean lifetime costs for both systematic case-finding and 
routine care are relatively low (less than £1500); however, this 
can be explained by the low incidence of COPD and a relatively 
low proportion of undiagnosed COPD in the starting cohort. 
Therefore, only a relatively small proportion of patients in the 
model will develop COPD over time and incur costs. Further-
more, in the case-finding strategy, as approximately only a third 
of patients respond to the questionnaire, only a small proportion 
will actually go onto receive spirometry and incur these addi-
tional costs.
We sought to explain why systematic case-finding was cost-ef-
fective despite the use of conservative assumptions, especially 
for treatment effectiveness. First, as our systematic case-finding 
approach was relatively inexpensive, only a small proportion 
of newly diagnosed patients needed to benefit from treatment 
for the intervention to be cost-effective. Second, once treat-
ment commenced, the risk of exacerbation and mortality were 
simultaneously reduced. Fewer exacerbations result in lower 
loss in QALYs as well as cost savings from fewer admissions 
to hospital. Reduced risk of mortality among treated patients 
results in greater accumulation of QALYs compared with their 
untreated counterparts. Overall, mortality did not have a signif-
icant impact on the ICER because treated patients who survived 
longer also consumed more healthcare resources. There are also 
further benefits from the effect of treatment on disease progres-
sion, and we also assumed a small utility benefit of being on 
treatment independent of disease progression and exacerbations. 
If this additional benefit was removed, then case-finding was no 
longer cost-effective.
Ten yearly systematic active case-finding was the most cost-ef-
fective screening interval, although policymakers need to balance 
this against a greater proportion of the cohort remaining undiag-
nosed for longer and the value patients and practitioners place 
on early diagnosis.38
To the best of our knowledge, this is the first model to evaluate 
the long-term cost-effectiveness of a COPD case-finding strategy. 
The reliability of the main data sources that informed the model 
was a notable strength. Patient-level data from the TargetCOPD 
trial, the Birmingham COPD cohort and THIN dataset provided 
up-to-date information on both diagnosed and undiagnosed 
patients with COPD in primary care in the UK.
Another strength was the use of conservative estimates of 
the treatment effect to prevent overestimation of the benefits 
of systematic case-finding. The natural history of COPD in 
untreated patients remains largely unknown. Here, we assumed 
that untreated and treated patients had the same natural history. 
In reality, undiagnosed patients may have a slightly poorer quality 
of life from suboptimal management and the disease progression 
rate might be faster.3 28
This study, however, does have several limitations. The first 
limitation is the uncertainty around the effect of treatment on 
progression from one GOLD stage to the next.39 40 This esti-
mate was not available in the literature. Although some previous 
studies have shown that treatment slows lung function decline 
(eg, changes in FEV1)
41 42, there is currently no clear method for 
transforming changes in FEV1 decline into risk ratios that could 
be used in this model. Nonetheless, the reduced lung function 
decline in treated patients is an indication that treatment may 
reduce risk of progressing to a worse GOLD stage. However, in 
order to explore the uncertainty regarding the impact of treat-
ment, extensive sensitive analyses were undertaken.
Additionally, the treatment effect as used in this model only 
captured the benefits associated with inhaled medications. Other 
interventions such as smoking cessation which has been shown 
to be effective in reducing COPD progression,43 pulmonary 
rehabilitation8 and self-management35 which improve HRQoL 
and reduce exacerbations, were not considered. Inclusion of 
other interventions would have made systematic case-finding 
more cost-effective but few patients receive these interventions, 
thereby making their wider benefit uncertain.
Another possible weakness is the use of the traditional GOLD 
staging criteria44 as airflow obstruction relates only weakly to 
quality of life. For instance, some patients with GOLD stage two 
may experience worse symptoms and impact than those with 
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Figure 4 Multiple one-way sensitivity analyses showing the relationship between ICER and (1) the effect of treatment on exacerbation, (2) the 
effect of treatment on mortality, (3) the effect of treatment on disease progression, (4) the yearly treatment initiation rate in newly diagnosed 
patients. Treatment effectiveness estimates are expressed as ORs. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
GOLD stage 3. Other symptom-based classification systems that 
are better predictors of prognosis now exist.45 However, there is 
no consensus regarding the most appropriate staging criteria, and 
the GOLD staging used here was the one used in previous litera-
ture that has informed inputs for assumptions used in the model.
We have also assumed that transitions between GOLD stages, 
exacerbation rates and utility values for undiagnosed states are 
the same as diagnosed (and untreated) GOLD stage health states. 
However, this assumption is supported by findings from cohort 
studies (eg, the CanCOLD study) that show that those with undi-
agnosed COPD have similar rates of health service use related to 
respiratory disease as those who have diagnosed COPD.3
Despite this, a further weakness lies in the assumption made 
regarding costs of undiagnosed disease. Only COPD-related 
costs are taken into account rather than all-cause costs. This may 
underestimate costs in the undiagnosed states, where there may 
be greater healthcare utilisation (eg, primary care visits) due to 
COPD, but the costs are not yet related to the condition. We 
also assume that untreated patients do not incur any healthcare 
cost until an admission for severe exacerbation occurs, whereas 
it is likely that some would have received prescriptions for their 
symptoms. However, it would be difficult to estimate these addi-
tional healthcare costs, and the conservative approach we have 
taken means that it is likely that case-finding would be more 
cost-effective with their inclusion.
A significant barrier to the implementation of case-finding 
programmes around the world has been the lack of evidence on 
whether the long-term benefit of early diagnosis and treatment 
outweighs the associated cost. Our economic model suggests that 
systematic case-finding leading to earlier diagnosis and treatment 
would provide benefits and value for money, despite uncertainty 
about treatment effectiveness in case-found patients and those with 
mild disease. The treatments would have to be almost completely 
ineffective on all important disease outcomes for regular case-
finding to be a worse option than current practice. However, we 
recognise that this is not a primary study, and it would be strength-
ened by better knowledge about the natural history of the disease 
and treatment effectiveness. Ultimately, data from a case-finding 
trial with longer term health outcomes would provide more 
robust evidence. We have also provided information on potential 
starting age and screening intervals. The exact configuration of 
such case-finding activity may however depend on local factors 
such as competing pressures on national budgets. A further need 
is to explore more fully patient views on earlier diagnosis and the 
overall financial impact on primary healthcare organisations of a 
much larger population of COPD patients to manage. Should a new 
programme of case-finding be implemented, a clear pathway of 
care would need to be provided in order to ensure newly diagnosed 
patients are optimally treated, as current data suggest that this is 
seldom the case.30
ConClusIon
We conclude that a 3-yearly systematic approach to case-finding 
is likely to be cost-effective in the long term given the current 
management of patients with COPD in primary care setting. The 
true importance of early diagnosis and treatment of COPD will 
be better understood as more evidence emerges on the effect of 
treatment on COPD and the longer term results of case-finding 
trials are available. Longer term follow-up of newly diagnosed 
patients may also further clarify the natural history of COPD.
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